[HTML][HTML] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free …
…, IA McNeish, A Dean, JW Kim, DM O'Donnell… - The Lancet, 2019 - thelancet.com
Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line
chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …
chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …
The use of eHealth to promote physical activity in cancer survivors: a systematic review
Purpose Achieving adequate levels of physical activity (PA) and avoiding sedentary behaviour
are particularly important in cancer survivors. eHealth, which includes, but is not limited to…
are particularly important in cancer survivors. eHealth, which includes, but is not limited to…
A novel serum microRNA panel to discriminate benign from malignant ovarian disease
Ovarian cancer is the seventh most common cancer in women and the most frequent cause
of gynaecological malignancy-related mortality in women. Currently, no standardized …
of gynaecological malignancy-related mortality in women. Currently, no standardized …
Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer
…, L Coate, D Delaney, DM O'Donnell… - European …, 2015 - Eur Respiratory Soc
The impact of host immunity on outcome in nonsmall cell lung cancer (NSCLC) is controversial.
We examined the relationship between lymphoid infiltration patterns in NSCLC and …
We examined the relationship between lymphoid infiltration patterns in NSCLC and …
[HTML][HTML] Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a …
…, IA McNeish, A Dean, JW Kim, DM O'Donnell… - The Lancet …, 2020 - thelancet.com
Background The ICON8 study reported no significant improvement in progression-free
survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly …
survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly …
Prevalence of insomnia in an oncology patient population: an Irish tertiary referral center experience
…, M O'Donnell, ST Lim, E Duff, DM O'Donnell… - Journal of the National …, 2020 - jnccn.org
Background: The NCCN Guidelines for Survivorship recommend dedicated sleep assessment.
Reported insomnia prevalence in the general Irish population is 6% to 15%. Reported …
Reported insomnia prevalence in the general Irish population is 6% to 15%. Reported …
OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions
…, PJ Selby, NT Georgopoulos, DM O'Donnell… - The Journal of …, 2008 - journals.aai.org
In vivo, dendritic cells (DC) are programmed to orchestrate innate and adaptive immunity in
response to pathogen-derived “danger” signals. Under particular circumstances, DC can …
response to pathogen-derived “danger” signals. Under particular circumstances, DC can …
[HTML][HTML] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from …
…, IA McNeish, A Dean, JW Kim, DM O'Donnell… - The Lancet …, 2022 - thelancet.com
Background Standard-of-care first-line chemotherapy for epithelial ovarian cancer is
carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported …
carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported …
Patients over 65 years are assigned lower ECOG PS scores than younger patients, although objectively measured physical activity is no different
…, J Hussey, MJ Kennedy, DM O'Donnell - Journal of geriatric …, 2014 - Elsevier
Objectives The Eastern Cooperative Group Performance Status (ECOG PS) is a widely used
standard functional classification in oncology practice, the verbal descriptors of which refer …
standard functional classification in oncology practice, the verbal descriptors of which refer …
[HTML][HTML] Circulating tumour cell numbers correlate with platelet count and circulating lymphocyte subsets in men with advanced prostate cancer: Data from the ExPeCT …
…, T Lynch, RP Manecksha, J McCaffrey, DM O'Donnell… - Cancers, 2021 - mdpi.com
Simple Summary Cancer cells (CTCs) can be found in the bloodstream in men with advanced
prostate cancer. Blood platelets, which normally help the blood to clot, may help the …
prostate cancer. Blood platelets, which normally help the blood to clot, may help the …